Article Detail - JE Part A
Self-Administered Drug Exclusion List (A53032) - R26 - Effective August 11, 2022
This coverage article has been revised and published for notice under contract numbers: 01111 (CA), 01211 (AS, GU, HI, NMI), 01311 (NV), and 01911 (CA, HI & Territories).
Effective Date: August 11, 2022
Summary of Changes:
The article is updated to remove: Tezspire™ (tezepelumab-ekko) - C9399, J3490, J3590 effective 07/17/2022.
*Note: J2356 assigned to Tezspire™ (tezepelumab-ekko) was also not added due to the removal.
The article is updated to add an asterisk to Skyrizi™ - C9399, J3490, J3590 as this drug has multiple routes of administration and must be billed with the appropriate modifier. - Effective 06/17/2022.
Visit the Self-Administered Drugs (SADs) webpage to view the Self-Administered Drug Exclusion List.
To view the complete listing of coverage articles and/or access the Active, Future, or Retired articles available in the CMS MCD, visit the Medicare Coverage Articles webpage.
Last Updated Fri, 12 Aug 2022 18:51:04 +0000